@drmoupali.bsky.social
Reposted
100% efficacy for HIV prevention.
That’s what the results from the PURPOSE 1 clinical trial showed. For her role in shaping studies around the first HIV drug to offer long-lasting protection, Moupali Das was a recipient of this year’s AAAS Mani L. Bhaumik Breakthrough of the Year Award.
That’s what the results from the PURPOSE 1 clinical trial showed. For her role in shaping studies around the first HIV drug to offer long-lasting protection, Moupali Das was a recipient of this year’s AAAS Mani L. Bhaumik Breakthrough of the Year Award.
July 17, 2025 at 2:11 PM
100% efficacy for HIV prevention.
That’s what the results from the PURPOSE 1 clinical trial showed. For her role in shaping studies around the first HIV drug to offer long-lasting protection, Moupali Das was a recipient of this year’s AAAS Mani L. Bhaumik Breakthrough of the Year Award.
That’s what the results from the PURPOSE 1 clinical trial showed. For her role in shaping studies around the first HIV drug to offer long-lasting protection, Moupali Das was a recipient of this year’s AAAS Mani L. Bhaumik Breakthrough of the Year Award.
Reposted
Lenacapavir has been approved by the FDA, a milestone in the fight to end HIV. Moupali Das & Yvette Raphael ensured those who would most benefit from the drug were included in clinical trials. They received the AAAS Bhaumik Breakthrough of the Year award for their roles in the drug’s development.
June 24, 2025 at 7:35 PM
Lenacapavir has been approved by the FDA, a milestone in the fight to end HIV. Moupali Das & Yvette Raphael ensured those who would most benefit from the drug were included in clinical trials. They received the AAAS Bhaumik Breakthrough of the Year award for their roles in the drug’s development.
Reposted
Drug-resistant gonorrhea, a form of the widespread sexually transmitted infection, is considered an urgent health threat worldwide. The US has just lost its ability to detect it.
www.nytimes.com/2025/04/04/h...
www.nytimes.com/2025/04/04/h...
A Federal Lab That Tracked Rising S.T.I.s Has Been Shuttered (Gift Article)
The United States can no longer keep tabs on drug-resistant gonorrhea, among other infections, scientists said.
www.nytimes.com
April 4, 2025 at 10:43 PM
Drug-resistant gonorrhea, a form of the widespread sexually transmitted infection, is considered an urgent health threat worldwide. The US has just lost its ability to detect it.
www.nytimes.com/2025/04/04/h...
www.nytimes.com/2025/04/04/h...
Reposted
Promising signs for ‘one jab a year’ PrEP.
We don’t have a vaccine to protect against HIV - but this is as good!
www.aidsmap.com/news/mar-202...
We don’t have a vaccine to protect against HIV - but this is as good!
www.aidsmap.com/news/mar-202...
Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise
As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...
www.aidsmap.com
March 18, 2025 at 8:50 AM
Promising signs for ‘one jab a year’ PrEP.
We don’t have a vaccine to protect against HIV - but this is as good!
www.aidsmap.com/news/mar-202...
We don’t have a vaccine to protect against HIV - but this is as good!
www.aidsmap.com/news/mar-202...
Reposted
Dr. Moupali Das from Gilead Sciences presented their Phase 1 results on once-yearly intramuscular lenacapavir for #HIVprevention.
Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/gilead-...
Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/gilead-...
Gilead's Once-Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study
New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
www.contagionlive.com
March 11, 2025 at 8:02 PM
Dr. Moupali Das from Gilead Sciences presented their Phase 1 results on once-yearly intramuscular lenacapavir for #HIVprevention.
Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/gilead-...
Study showed that both formulations sustained high drug concentrations for over 56 weeks. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/gilead-...
Reposted
Colleen Kelley MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development. #CROI #croi2025
#IDsky #IDMed
#IDsky #IDMed
HIV Prevention: Discussing PrEP, PEP, and Vaccine Development
Colleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vacci...
www.contagionlive.com
March 13, 2025 at 5:22 PM
Reposted
Dr. Avihingsanon, Principal Investigator of the ALLIANCE study explained that after 48 weeks of open-label extension w/ B/F/TAF, 95.4% of participants maintained HIV RNA suppression & 86.6% achieved HBV DNA suppression. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/allianc...
www.contagionlive.com/view/allianc...
ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV Suppression
Anchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.
www.contagionlive.com
March 18, 2025 at 1:18 PM
Dr. Avihingsanon, Principal Investigator of the ALLIANCE study explained that after 48 weeks of open-label extension w/ B/F/TAF, 95.4% of participants maintained HIV RNA suppression & 86.6% achieved HBV DNA suppression. #CROI2025 #IDsky #MEDsky #HIVsky
www.contagionlive.com/view/allianc...
www.contagionlive.com/view/allianc...
Reposted
ICYMI: Dr. Moupali Das presented data at #CROI2025 showing Gilead's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. This phase 1 study paves the way for improved adherence & HIV prevention. #IDsky #HIVsky #MEDsky
Learn more: www.contagionlive.com/view/gilead-...
Learn more: www.contagionlive.com/view/gilead-...
March 19, 2025 at 3:59 PM
ICYMI: Dr. Moupali Das presented data at #CROI2025 showing Gilead's once-yearly Lenacapavir formulations for HIV PrEP sustain efficacy for 56 weeks. This phase 1 study paves the way for improved adherence & HIV prevention. #IDsky #HIVsky #MEDsky
Learn more: www.contagionlive.com/view/gilead-...
Learn more: www.contagionlive.com/view/gilead-...
Reposted
Top 5 HIV stories from #CROI2025 include new treatments, insights on #HIV remission, etc. Key updates include Gilead's once-yearly lenacapavir for PrEP, bictegravir vs darunavir in advanced HIV, & early data on Immunocore’s IMC-M113V. #IDsky #MEDsky #HIVsky
🔒: www.contagionlive.com/view/top-5-h...
🔒: www.contagionlive.com/view/top-5-h...
Top 5 HIV Stories from CROI 2025: New Treatments, HIV Remission Insights, and More
Studies presented included once-yearly lenacapavir formulations for PrEP, bictegravir outperforming darunavir in advanced HIV, Immunocore's IMC-M113V showing viral control and reservoir reduction, and...
www.contagionlive.com
March 21, 2025 at 6:31 PM
Reposted
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
www.technologyreview.com
March 14, 2025 at 1:32 PM
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.